Yield10 Bioscience Inc Stock Price, News & Analysis

Yield10 Bioscience (Nasdaq:YTEN) has announced a scale-up of its Camelina line E3902 seed production aimed at providing low-carbon feedstock oil for the renewable diesel market. In 2022, the company plans to advance field testing of herbicide-tolerant Camelina lines as part of its commercialization efforts. The E3902 line has demonstrated a 5% increase in seed oil content. Demand for renewable diesel is rising in the U.S. and Canada, driven by a shift toward low-carbon fuels. Yield10 aims to position Camelina as a competitive feedstock in this expanding market.

Yield10 Bioscience, Inc. (Nasdaq:YTEN) announced it will report its Q4 and full year 2021 financial results on March 9, 2022. The company will hold a conference call at 4:30 p.m. ET to discuss the financial outcomes and provide a corporate update, followed by a Q&A session. Interested parties can access the call via phone or live webcast. Additionally, a replay will be available for two weeks post-call. Yield10 focuses on developing improved Camelina varieties for agricultural applications and aims to commercialize high-value seed products.

Yield10 Bioscience (Nasdaq: YTEN) reported promising results from its 2021 field tests for oil content traits C3020 in Camelina and C3007 in canola. C3020 demonstrated a seed oil content increase of up to 9%, while C3007 achieved around 5%. Further testing is scheduled for spring 2022. The company is positioning itself to meet the rising demand for renewable diesel feedstocks, capitalizing on the projected growth in the vegetable oil market. Their innovative approach may enhance the economic value of oilseed crops.

Yield10 Bioscience announced a favorable ruling from Argentina's CONABIA, confirming that three CRISPR genome-edited Camelina lines are similar to conventional varieties. This classification allows Yield10 to market these lines without pre-market authorizations. The E3902 line has demonstrated a 5% increase in seed oil content compared to controls. This decision streamlines the company's operations in Argentina, enhancing its ability to scale up seed production aimed at high-value markets, particularly in oil and meal production targeting aquaculture.

Yield10 Bioscience has appointed Darren Greenfield as the new Senior Director of Seed Operations, effective immediately. With over 25 years of experience in the agriculture sector, Greenfield will focus on scaling up Camelina seed production. His prior roles include work with BASF and Dow Agrosciences. Yield10 aims to enhance its seed products pipeline, targeting biofuel feedstock demands and planning to launch new varieties, including omega-3 nutritional oils. This leadership change is expected to strengthen operations and drive growth in the commercial market.

Yield10 Bioscience, Inc. (Nasdaq: YTEN) announced that President and CEO Oliver Peoples, Ph.D. will present at the H.C. Wainwright Bioconnect Investment Conference, held virtually from January 10-13, 2022. The presentation will be available starting at 7:00 a.m. ET on January 10. Additionally, Yield10 management will participate in one-on-one meetings with registered investors. The company focuses on developing enhanced Camelina varieties and high-value genetic traits for the agriculture industry.

Yield10 Bioscience (Nasdaq: YTEN) has announced its participation in the Benzinga Global Small Cap Conference on December 9, 2021. President and CEO Oliver Peoples, Ph.D. will present at 10:30 AM EST, followed by one-on-one meetings with registered investors. An archived replay of the presentation will be accessible via the conference website. Yield10 focuses on agricultural bioscience, utilizing its Trait Factory platform to develop superior Camelina varieties and high-value genetic traits for various crops.

Yield10 Bioscience announced Dr. Kristi Snell's presentation at the Canola Week 2021 Conference from November 30 to December 2, 2021. She will discuss "Genome editing to increase seed oil in Camelina" using CRISPR technology during the session on December 2. The company is developing novel traits to boost seed oil content in oilseed crops, specifically focusing on the E3902 line created through genome editing. This initiative aligns with the rising demand for oil feedstock for renewable diesel in North America.

Yield10 Bioscience (Nasdaq:YTEN) announced its financial results for Q3 2021, reporting a net loss of $2.4 million, or $0.49 per share, compared to a net loss of $2.2 million, or $0.87 per share, in Q3 2020. The company has $18.5 million in unrestricted cash and investments, a decrease from $20.6 million in Q2 2021. Yield10’s operational progress includes successful PHA bioplastic seed scale-up and ongoing trials for its winter Camelina varieties, targeting biodiesel market opportunities. The company expects to fund operations into Q2 2023, pending additional financing.